Novo Nordisk Q2 Preview: Focus On Rybelsus, Ozempic And Payors
Semaglutide’s Obesity Prospects Another Key Topic
Executive Summary
Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.